Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Mineralys Therapeutics Inc (NASDAQ: MLYS) closed the day trading at $37.16 down -3.63% from the previous closing price of $38.56. In other words, the price has decreased by -$3.63 from its previous closing price. On the day, 2.03 million shares were traded. MLYS stock price reached its highest trading level at $39.2 during the session, while it also had its lowest trading level at $37.09.
Ratios:
For a better understanding of MLYS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30. On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 04 ’25 when AKKARAJU SRINIVAS bought 588,235 shares for $25.50 per share. The transaction valued at 14,999,992 led to the insider holds 588,235 shares of the business.
RA CAPITAL MANAGEMENT, L.P. bought 1,176,470 shares of MLYS for $29,999,985 on Sep 04 ’25. The Director now owns 5,456,521 shares after completing the transaction at $25.50 per share. On Aug 13 ’25, another insider, Rodman David Malcom, who serves as the Chief Medical Officer of the company, sold 11,365 shares for $12.93 each. As a result, the insider received 146,987 and left with 92,891 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 2991086336 and an Enterprise Value of 2231426304.
Stock Price History:
The Beta on a monthly basis for MLYS is -0.52, which has changed by 2.159864 over the last 52 weeks, in comparison to a change of 0.17089343 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $38.62, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 112.98%, while the 200-Day Moving Average is calculated to be 164.14%.
Shares Statistics:
Over the past 3-months, MLYS traded about 1.38M shares per day on average, while over the past 10 days, MLYS traded about 4227150 shares per day. A total of 65.73M shares are outstanding, with a floating share count of 42.81M. Insiders hold about 35.42% of the company’s shares, while institutions hold 75.65% stake in the company. Shares short for MLYS as of 1756425600 were 7617115 with a Short Ratio of 5.53, compared to 1753920000 on 6996921. Therefore, it implies a Short% of Shares Outstanding of 7617115 and a Short% of Float of 15.100000999999999.
Earnings Estimates
The current market rating for Mineralys Therapeutics Inc (MLYS) reflects the collective analysis of 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.48 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.35 and -$3.44 for the fiscal current year, implying an average EPS of -$2.72. EPS for the following year is -$2.65, with 7.0 analysts recommending between -$1.89 and -$3.43.
